Abstract: OBJECTIVE: To investigate Survivin，Cox-2 protein and risk factors in non-small cell lung cancer (NSCLC) with a systematic review. METHODS：The published studies were searched in the Cochrane Library (Issue 1，2011)，Pubmed and CNKI databases，and other relevant journals were also handsearched to identify all the relevant case-control trials. Then the quality of the included trials was assessed and meta-analysis were performed by RevMan 4.2.10 software. RESULTS：For Survivin，including 1 222 cases and 447 controls in 15 studies，the positive rate showed significant differences between NSCLC and normal lung tissues (OR=11.11，95%CI=5.92-20.83，P＜0.05). There were significant differences between T stagesⅢ-Ⅳ and stagesⅠ-Ⅱ，clinic stages Ⅲ-Ⅳ and stagesⅠ-Ⅱ，lymph node metastasis and non-lymph node metastasis，cell differentiation G3 and cell differentiation G1-G2(P＜0.05). For Cox-2，including 975 cases and 209 controls in 12 studies，the positive rate of expression revealed significant differences between NSCLC and normal lung tissues (OR=29.46，95% CI=15.91-54.56，P＜0.05). No significant difference was found between T stagesⅢ-Ⅳ and stagesⅠ-Ⅱ(P >0.05). There were significant differences between clinic stages Ⅲ-Ⅳ and stagesⅠ-Ⅱ， lymph node metastasis and non-lymph node metastasis，cell differentiation G3 and cell differentiation G1-G2(P＜0.05). CONCLUSION：Survivin，Cox-2 expression increased malignant behaviors of NSCLC，with substantial correlation confirmed between Survivin and Cox-2.

Key words: non-small cell lung cancer, Survivin, Cox-2, systematic review